Log in or Sign up for Free to view tailored content for your specialty!
Oncology News
Regular vigorous exercise reduces liver cancer risk
Regular vigorous physical activity reduced the risk for hepatocellular carcinoma by approximately 45%, according to recently published data.
Oncimmune expands access to cancer risk lung, liver blood tests
Oncimmune Holdings entered into an agreement with America’s Choice Provider Network to expand access to the company’s EarlyCDT-Lung and EarlyCDT-Liver blood tests, designed to assess cancer risks, according to a press release.
Log in or Sign up for Free to view tailored content for your specialty!
Incident diabetes increases risk for liver cancer, hepatic diseases
Diabetes and high blood glucose levels among individuals without known diabetes correlated with increased risks for liver cancer and chronic liver disease, according results of a Chinese cohort study.
10 video highlights from 2018 hepatology meetings
Every year, Healio Gastroenterology and Liver Disease meets with hepatology and gastroenterology experts to discuss their presentations on the latest research data, therapeutic updates, and recent advocacy programs.
Adherence to ‘Healthy Eating Index’ diet may reduce liver cancer risk
Adherence to the Alternative Healthy Eating Index2010 dietary pattern may reduce the risk for hepatocellular carcinoma, according to a study published in Hepatology.
Extrahepatic cancer risk increases after HCV SVR
Extrahepatic cancer was more common in patients with hepatitis C and was the leading cause of death in patients who achieved sustained virologic response compared with the general population, according to results of a French cohort study.
FDA grants orphan drug designation to M7824 for biliary tract cancer
The FDA granted orphan drug designation to M7824 for the treatment of biliary tract cancer.
Sorafenib with TACE improves response to HCC, not overall survival
Sorafenib combined with conventional transarterial chemoembolization for patients with advanced hepatocellular carcinoma improved time to progression, progression-free survival, and tumor response rate compared with sorafenib alone, according to a recently published study.
CheckMate-040: Opdivo may present an option for Child-Pugh B HCC
SAN FRANCISCO — Patients with advanced hepatocellular carcinoma with Child-Pugh B status experienced encouraging efficacy and safety outcomes after treatment with PD-1 inhibitor Opdivo, according to data presented at The Liver Meeting 2018.
DAAs reduce HCC, decompensation risk compared with no treatment
SAN FRANCISCO — Individuals with hepatitis C who underwent DAA therapy experienced significant reductions in both hepatocellular carcinoma and decompensation risk compared with untreated patients, according to data presented at The Liver Meeting 2018.
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read